-
Join 37 other subscribers
Categories
Top Posts
Blogroll
Tag Archives: M&A
AbbVie will buy Shire in another Pharma tax inversion strategy
Following on the heels of Mylan, AbbVie will buy Shire in a move that, among other things, will result in a significantly lower tax rate when the redomiciled company is fully headquartered in Ireland. More information can be found here (WSJ) and here … Continue reading
Posted in Economics, Pharmaceutical Industry
Tagged AbbVie, corporate tax rates, M&A, Shire, tax inversion
1 Comment
Pharma megamergers — against the spirit of the times?
Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday. As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading
Posted in Fixing Big Pharma Research, Pharmaceutical Industry
Tagged Eli Lilly, GSK, M&A, megamergers, Novartis, Pfizer, Pharmaceutical industry
1 Comment
Pharma deal frenzy points to fundamental change in strategy
Pharmaceutical giants Novartis and GSK announced a large swap in business units on Tuesday, resulting in both companies becoming significantly more specialized — reversing their decades-long traditional strategies of greater diversification across product lines. The Wall Street Journal has more than … Continue reading
Posted in Pharmaceutical Industry
Tagged Consolidation, GSK, M&A, Novartis, Pharmaceutical industry, Specialization
1 Comment